natgillin/translations-raw huggingface dataset:
when said tablet is flattened without breaking to no more than about 60% of its thickness before flattening, said flattened tablet has an in-vitro dissolution, when measured in a USP Apparatus 1 (basket) at 100 rpm and at 37° C. in 900 ml of simulated gastric fluid having no enzymes and having 40% ethanol, wherein the percent amount of said opioid hydrochloride salt released at 0.5 hours of dissolution deviates no more than about 15% from the corresponding in-vitro dissolution without ethanol; 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 14, pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 °C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37° C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 i 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
Method in accordance with claim 22 in which, after the block is rendered and before insertion in the wall or roof, the frame is mounted on said block. 
Metoda prema zahtjevu 21, naznačena time da je nakon što je blok (1,2) ožbukan i prije umetanja u zid (5) ili krov, okvir (10) montiran na navedeni blok (1,2).
The thermoplastic film according to any preceding numbered embodiment, wherein the base film and the fibre element are prestretched by at least 10%, preferably by at least 50%, preferably by at least 100%, more preferably by at least 200%. 
Termoplastična folija sukladno bilo kojem od prethodnih zahtjeva, pri čemu su osnovna folija 1 element vlakana prethodno rastegnuti za barem 10%, poželjno za barem 50%, poželjno za barem 100%, poželjnije za barem 200%.
A compound according to claim 9, wherein R1 is (C2-C6)alkenyl, aryl-S- or aryl(C1-C6)alkyl, wherein said aryl as part of another group is substituted with 1 or 2 substituent(s) R6; 
je (C2-C6)alkenil, aril-S- ili aril(C1-C6)alkil, pri čemu je rečeni aril kao dio druge skupine supstituiran s 1 ili 2 supstituenta R6;
The antibody according to claim 38, wherein the hydrophobic organic agent comprises an aldehyde. The antibody according to claim 38, wherein the hydrophobic organic agent is selected from the group consisting of 4-hydroxy-2-nonenal, malondialdehyde, 4-oxo-2-nonenal, and acrolein, and any combination thereof. 
Lijek za uporabu prema zahtjevu 11 ili zahtjevu 13, ili antitijelo prema zahtjevu 12 ili zahtjevu 13, pri čemu stabilizirani protofibril a-sinukleina sadrži protofibril a-sinukleina koji je modificiran s hidrofobnim organskim agensom odabranim iz skupine koja se sastoji od 4-hidroksi-2-nonenala, malondialdehida, 4-okso-2-nonenala i akroleina, i bilo koje njihove kombinacije.
In such AvPAL variants pegylation may be achieved by reacting the AvPAL variant with a water-soluble polymer PEG. 
(£) pegiliranju varijante AvPAL miješanjem polietilen-glikola s varijantom AvPAL;
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 6, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 14, pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 °C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37° C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 i 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
The formulation according to claim 1, containing the following ingredients, in percentages by weight of the total weight of the formulation: 
Formulacija prema patentnom zahtjevu 1, koja sadrži sljedeće sastojke, u težinskim postocima na ukupnu težinu formulacije:
The method of claim 32, wherein the disease is neutrophilic asthma. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest neutrofilna astma.
The light stabilising composition according to the invention may suitably include additives such as anti-oxidants, emulsifiers and carrier materials. 
Pripravak za stabiliziranje na svjetlo prema izumu može prikladno uključivati aditive kao što su antioksidanti, emulgatori i nosači.
A pharmaceutical composition comprising crystalline form IV of posaconazole as defined in any one of claims 1 to 6 and optionally a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da sadrži kristalni oblik IV posakonazola određen prema zahtjevu 1 ili 2 i po želji farmaceutski prihvatljiv nosač.
at least a C6-C12-dicarboxylic acid, ester, amide and/or a physiologically acceptable salt thereof. 
najmanje nerazgranati i/ili amid alkil C6-C12-dikarboksilne kiseline i/ili njegovu fiziološki prihvatljivu sol.
The fungicidal composition according to Claim 1, wherein the mixing weight ratio of (a) to (b) is from 1:5,000 to 5,000:1. 
Fungicidni pripravak u skladu s patentnim zahtjevom 1, naznačen time, da težinski omjer od (a) do (b) je od 1:5,000 do 5,000:1.
The redox flow battery of claim 16, wherein the leakage preventing part is provided with a cutout hole being connected to at least one of an inflow path into which the electrolyte is introduced from the flow path frame through the common flow path and an outflow path conveying the electrolyte to the impregnation part. 
Baterija s redoks protokom u skladu s patentnim zahtjevom 13, naznačena time, da je dio za sprječavanje istjecanja (510, 520) opremljen izrezanom rupom koja je povezana ili s dovodnom putanjom u koju se elektrolit dovodi iz okvira za putanju protoka preko zajedničke putanje protoka ili s odvodnom putanjom koja prenosi elektrolit na dio za impregnaciju.
A method in accordance with claim 3, 5, 6 or 7 characterised by that the alignment step is interrupted before the conductive pathway has reached through the layer and connected the alignment electrodes. 
Postupak u skladu s patentnim zahtjevom 3, 5, 6 ili 7 naznačen time što se korak poravnavanja prekida prije nego vodljivi put dosegne kroz sloj i spoji s poravnavajućim elektrodama.
A number of embodiments of the invention have been described. 
23.03.2007, (96) Broj europske prijave patenta:
A pharmaceutical composition according to claim 6 wherein the composition is suitable for oral administration. 
Farmaceutski pripravak prema zahtjevu 6, naznačen time, da je pripravak pogodan za oralno davanje.
n is 0-2; or a pharmaceutically acceptable salt thereof. This invention also relates to compounds of Formula (I)(A), wherein A is a 5-membered heterocyclic ring, which may contain 0-2 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, —C(O)Ra, —SO2Ra, arylalkyl, —(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što je A 5-eročlani heterociklički prsten, koji može sadržavati 0-2 dvostruke veze i može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C;-Cgalkil, supstituirani C;-Cgalkil, C3-Czcikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R., arilalkil, (C;-C;alkiljariloksi, aril, heteroaril i C;-Cgalkoksi, gdje je svaki R, neovisno C;-CÂ«alkil, supstituirani C;- Csalkil ili nesupstituirani C2-Crcikloalkil; svaki R> i R3 je neovisno vodik, C,-Cgalkil, supstituirani C,-Cgalkil, halogen, hidroksil, amid, karboksilna kiselina ili C,-C,alkoksi;
The mouse according to claim 8 or 12,wherein the mouse further comprises at an endogenous B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide. 
Miš prema zahtjevu 8 ili 12, naznačen time, da miš nadalje na endogenom fB2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid.
The mixture stirred for 4 h while gradually warming to room temp. before diluting with EtOAc. The mixture was washed with water and brine and dried (Na2SO4) before concentrating to give a dark oil. 
Smjesa je miješana 4 sata uz istovremeno postepeno zagrijavanje do sobne temperature, prije razrjeđivanja sa FtOAc., Smjesa je isprana vodom i slanom otopinom i sušena (Na2SO;) prije koncentriranja kojim se dobije tamno ulje.
The fluid inlet may be connected to a water reservoir via a flexible tube for flushing clean water through the fluid channel and out of said fluid exit into the organ. 
Ulazni otvor za fluid može biti spojen na spremnik s vodom preko savitljive cijevi radi dobavljanja mlaza čiste vode kroz kanal za fluid i zatim dobavljanje tog fluida iz izlaznog otvora za fluid u organ.
An isolated IL-23p19 antibody fragment, comprising a light chain variable region comprising: 
pri čemu varijabilna regija laganog lanca sadrži:
preparing a homogeneous melt of said HIV protease inhibitor (s), said water- soluble polymer (s) and said surfactant (s), and 
pripremu homogene taline inhibitora proteaze HIV-a, polimera topljivog(topljivih) u vodi i surfaktan(a)ta, i
number: 3 consecutive measurements, 
Broj europske prijave patenta:
Fuel gas supply system and method of a ship 
SUSTAV I POSTUPAK DOBAVE POGONSKOG PLINA ZA BROD
and R3 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C1-C3 haloalkyl group or a linear or branched C1-C3 alkyl group; 
i R3 svaki zasebno predstavljaju atom vodika, atom halogena, cijano grupu, C1-C3 haloalkilnu grupu ili linearnu ili razgranatu C1-C3 alkilnu grupu;
The method as claimed in one of claims 1 to 4, in which two or more longitudinal bars (6, 7, 7') have a different diameter. 
Postupak prema jednom od patentnih zahtjeva 1 do 4, naznačen time, da dvije ili više uzdužnih šipki (6, 7, 7 ') imaju različit promjer.
R3 and R'3 together with the carbon atom to which they are attached can form an unsubstituted cyclopropyl. 
R3 i R3 zajedno s atomom ugljika na koji su vezani tvore C3.7 cikloalifatski;
If said maximum sampled value is acceptable, it is stored as test-value, imposed by the GFCI 1, and next phase VII is reached. 
Ako je maksimum uzorkovane vrijednosti unutar dozvoljenih vrijednosti, isti se sprema kao testna vrijednost i prelazi se na fazu VII.
The strability of omeprazole sodium salt, of the invention, obtained according to Example 1, was compared with the stability of the neutral form of omeprazole. 
Stabilnost omeprazol natrij soli, iz izuma, koja je dobivena prema Primjeru 1, uspoređena je sa stabilnošću neutralnog oblika omeprazola.
The compound of claim 1, wherein each of R1,R2 and R3 is methyl, or wherein each of R24 is hydrogen, or wherein Ra and Rb are each independently hydrogen or methyl, or wherein Ra and Rb are each methyl, or wherein Rc and Rd are each independently hydrogen or lower alkyl, or wherein Rc and Rd are each lower alkyl or wherein Rc and Rd are each hydrogen; and wherein V is: or and wherein lower alkyl is defined in claim 1. 
Spoj prema zahtjevu 1, naznačen time da svaki od R1,R2 i R3 je metil, ili pri čemu svaki od R24 je vodik, ili pri čemu Ra i Rb su svaki neovisno vodik ili metil, ili pri čemu Ra i Rb su svaki metil, ili pri čemu Rc i Rd su svaki neovisno vodik ili niži alkil, ili pri čemu Rc i Rd su svaki niži alkil ili pri čemu Rc i Rd su svaki vodik; te pri čemu V je: [image] [image] ili [image] i pri čemu niži alkil je definiran u zahtjevu 1.
The application claims the benefit of the International Patent Application No. 
EP 09844238.7 Datum podnošenja europske prijave patenta:
detecting in the genomic DNA the absence of an insertion in the nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 3 by using a molecular marker, isolating the nucleotide sequence without the insertion, and introducing the isolated [a]nucleotide sequence without the insertion into a plant or plant part. 
detektiranja odsutnosti insercije u kodirajućem nukleotidnom slijedu molekule nukleinske kiseline u skladu s patentnim zahtjevom 1; ili detektiranja najmanje jedne polimorfije kao na Slikama 1, 2 i/ili 3 u kodirajućem nukleotidnom slijedu molekule nukleinske kiseline u skladu s patentnim zahtjevom 1 upotrebom molekulskih biljega, koji detektiraju polimorfiju.
A method of making an alcoholic beverage according to claim 1, comprising the step of adding to a beverage a deuterated alcohol having the formula wherein each H may independently be hydrogen or deuterium. 
Postupak za pravljenje alkoholnog pića prema patentnom zahtjevu 1, naznačen time što obuhvaća korak dodavanja piću deuteriranog alkohola koji ima formulu pri čemu svaki H može nezavisno biti vodik ili deuterij.
The waste trap (10) of claim 11, wherein a base of the cup rests on the bottom surface of the body. 
Sifon (10) prema patentnom zahtjevu 11, gdje je osnova čaše leži na donjoj površini tijela.
Thus in a first embodiment (a), the present invention concerns compressed tablets preferably direct compressed pharmaceutical tablets, wherein the dispersion contains particles comprising DPP-IV inhibitor preferably LAF237, in free form or in acid addition salt form, and wherein at least 60%, preferably 80% and most preferably 90% of the particle size distribution in the tablet is less than 250 µm or preferably between 10 to 250 µm. 
Direktno komprimirana farmaceutska tableta, naznačena time, da tablet obuhvaća sljedeće: a) od 22 do 28 masenih postotaka na bazi suhe mase inhibitora DPP-IV koji je (S)-1-[(3-hidroksi-1- adamantil)aminolacetil-2-cijanopirolidin u slobodnom obliku ili u obliku kiselinske adicijske soli; b) od 45 do 50 masenih postotaka na bazi suhe mase farmaceutski prihvatljive mikrokristalne celuloze;
The effect may include, for example, treatment or prevention of the conditions listed herein. 
Učinak može uključivati, npr., liječenje ili prevenciju kod stanja koja su ovdje spomenuta.
The fusion protein of claim 3, wherein the tag is a carboxy terminal hexa-histidine. A method of treating a condition related to increased expression TGFB comprising administering an effective amount of the fusion protein of claim 1 to subject in thereof. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u postupku liječenja stanja povezanog s pojačanom ekspresijom TGFR, koja se sastoji u primjeni djelotvorne količine fuzijskog proteina na subjektu kojem je to potrebno.
The said mineral matter used in the method of the invention preferentially has a percentage by weight of particles having a diameter of less than 2 um, measured by a Sedigraph™ 5100, of between 5% and 90%, and more preferentially between 10% and 60% at the supply of the air classifier in step d). 
Postupak prema jednom od zahtjeva 1 do 22, naznačen time da navedeni mineralni materijal ima težinski postotak čestica koje imaju promjer od manje od 2 pm, mjeren sa uređajem SedigraphTM 5100, od između 5% 1 90%, poželjno između 10% 1 60% na ulazu razvrstavanja pomoću zraka iz koraka d).
An L-malate salt of compound-1 having the formula: 
Sol L-malata koja sadrži formulu:
wherein Ra and Rb independently represent hydrogen, or a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom); 
gdje R* i R* nezavisno predstavljaju, pri svakom pojavljivanju, vodik, ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, 1li heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom; i nje 0, 1, 2,3 ili 4; ili farmaceutski prihvatljiv solvat ili, pobliže, njenu sol; za uporabu u liječenju osteoporoze i/ili osteopenije.
a heavy chain variable region CDR1 of SEQ ID NO: 5; a heavy chain variable region CDR2 of SEQ ID NO: 12; a heavy chain variable region CDR3 of SEQ ID NO: 19; a light chain variable region CDR1 of SEQ ID NO: 26; a light chain variable region CDR2 of SEQ ID NO: 33; and a light chain variable region CDR3 of SEQ ID NO: 40; or 
(d) CDRI varijabilno područje jakog lanca od SEQ ID NO:5; CDR2 varijabilno područje jakog lanca od SEQ ID NO:12; CDR3 varijabilno područje jakog lanca od SEQ ID NO:19; CDRI varijabilno područje slabog lanca od SEQ ID NO:26; CDR2 varijabilno područje slabog lanca od SEQ ID NO:33; i CDR3 varijabilno područje slabog lanca od SEQ ID NO:40; ili
The method according to claim 1, wherein forming the final hole comprises removing plant tissue from the stem of the plant during the formation of the initial hole and additionally or alternatively during extending the size of the initial hole. The method according to claim 1, wherein the plant is a potted plant. 
Postupak prema zahtjevu 1, naznačen time da formiranje završnog otvora sadrži uklanjanje biljnog tkiva iz stabljike (S) biljke (P), poželjno tijekom oblikovanja početnog otvora (IH) i dodatno ili alternativno tijekom proširivanja veličine početnog otvora (IH).
CHO cells stably transfected with an expression vector encoding hRUP25 and cultured under condition permissive for cell surface expression of the encoded hRUP25 receptor were harvested from flasks via non-enzymatic means. 
CHO stanice stabilno transfektirane pomoću ekspresijskog vektora koji kodira hRUP25 i kultivirane uz uvjete dopustive za ekspresiju stanične površine za kodirani hRUP25 receptor su pokupljene iz tikvice na ne-enzimatski način.
A modified serpin according to claim 1 wherein the mutations in the RCL of the modified serpin consist of mutations at positions P1′ and P2; positions P1′, P2 and P1; positions P1′, P2 and P4; or positions P1′, P2, P4 and P1. 
Modificirani serpin prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se mutacije u RCL-petlji od modificiranog serpina, sastoje od mutacija na pozicijama P1' i P2; pozicijama P1', P2 i P1; pozicijama P1', P2 i P4; ili pozicijama P1', P2, P4 i P1.
detecting the presence of a signal from the first detectable entity in the test region, wherein the presence of the signal is indicative of the presence of the antibody in the test sample. 
(c) detektiranju prisutnosti signala iz prvog detektibilnog entiteta u ispitivanom području, gdje prisutnost signala ukazuje na prisutnost protutijela u ispitivanom uzorku.
PCT Patent Application Publication WO 01/37860 
Datum objave europske prijave patenta:
The monolithic intravaginal ring of claim 1, wherein the intravaginal ring comprises: 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da intravaginalni prsten sadrži:
The process of claim 24, wherein the basic lithium alkylamide is lithium diisopropylamide. 
Postupak sukladno patentnom zahtjevu 16, naznačeno time da je navedeni bazni litij alkilamid litij diizopropilamid.
A platform comprising a solid support wherein said solid support comprises an indentation capable of acting as a receptacle for a sample with a possible microbial infection or contamination, said indentation being divided into three or more compartments, each compartment containing a test composition or a control composition and one or more integrated dividing members for dividing said indentation into said separate compartments, wherein said test composition comprises a semi solid microbial growth medium, an antimicrobial and three or more chromogenic substrates selected from the group consisting of 5-Bromo-6-chloro-3-indolyl phosphate, 5-Bromo-4-chloro-3-indolyl-B-D-galactopyranoside, 5-Bromo-6-chloro-3-indolyl-B-D-galactopyranoside, 6-Chloro-3-indolyl-B-D-galactopyranoside, 5-Bromo-4-chloro-3-indolyl-B-D-glucopyranoside, 5-Bromo-4-chloro-3-indolyl-B-D-glucuronide; 
HR P20140019 T1 PATENTNI ZAHTJEVI Platforma koja obuhvaća čvrstu podlogu, pri čemu ta čvrsta podloga ima udubljenje koje može poslužiti kao dio u koji se stavlja uzorak moguće mikrobno inficiran ili onečišćen, to udubljenje podijeljeno je na dva ili više odjeljka, svaki odjeljak sadrži testnu smjesu ili kontrolnu smjesu, te jedan ili više integriranih razdjelnika koji dijele to udubljenje u spomenute zasebne odjeljke, gdje i) testna smjesa sadrži polučvrsti medij za rast mikroba, antimikrobno sredstvo i tri ili više kromogena supstrata izabrana iz grupe koja obuhvaća 5-Brom-6-klor-3-indolil fosfat, 5-Brom-4-klor-3-indolil-B-D-galaktopiranozid,
Synthesis of compounds of the invention: 
Datum objave europskog patenta:
The structural loop regions of the variable domain of the immunoglobulin of human origin comprise preferably amino acids 8 to 20, amino acids 44 to 50, amino acids 67 to 76 and amino acids 89 to 101. According to a preferred embodiment of the present invention the structural loop regions of the variable domain of the immunoglobulin of murine origin comprise amino acids 6 to 20, amino acids 44 to 52, amino acids 67 to 76 and amino acids 92 to 101. 
Postupak u skladu sa zahtjevom 15 ilil6, naznačen time, da imunoglobulin obuhvaća neko od podučja strukturne petlje varijabilne domene koja sadrže modifikaciju u jednom vanjskom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 20, aminokiseline 44 do 50, aminokiseline 67 do 76 i aminokiseline 89 do 101, pri čemu je numeriranje prema IMGT.
the fitting of a following strip of flexible material over the top face and a side face of the following core element, as well as over that bottom portion of the template which adjoins this side face, 
- - postavljanje sljedeće trake od fleksibilnog materijala (2%) preko predjela na dnu (3) kalupa (4), koji se nalazi uz tu bočnu stranu (6%).
Thus, “BTDS 5” contains about 5 mg buprenorphine. 
Tako, "TSB 5" sadrži približno 5 mg buprenorfina.
A conjugate of formula ConjB: where CBA represents a cell binding agent. 
ConjB gdje CBA predstavlja stanično vezno sredstvo.
A composition comprising by way of active principle a compound consisting of an antibody, or one of its functional fragments, as claimed in one of claims 3-23, 26, 27, 30, 31 and 33-36 or produced by hybridoma according to claims 24, 25, 28, 29 or 32. 
Pripravak koji kao aktivni sastojak sadrži spoj koji se sastoji od antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met kao što je prijavljeno u jednom od patentnih zahtjeva 1, 2 te 4 - 8 ili je dobiven metodom iz patentnog zahtjeva 12, ili je dobiven pomoću hibridoma prema patentnom zahtjevu 3.
Pharmaceutical formulation according to any one of Claims 8 to 10, in which the pharmaceutical formulation is chosen from the group comprising tablets, capsules, coated tablets, granules, solutions and syrups for oral administration, antiseptic plasters, solutions, pastes, creams and ointments for transdermal administration, suppositories for rectal administration, sterile solutions for injection or aerosol administration, in either immediate-release or sustained-release form. 
Farmaceutska formulacija prema bilo kojem od zahtjeva 8 do 10, naznačena time, da je farmaceutska formulacija odabrana iz skupine koju čine tablete, kapsule, obložene tablete, granule, otopine i sirupi za oralnu primjenu, antiseptički flasteri, otopine, kaše, kreme i masti za transdermalnu primjenu, supozitoriji za rektalnu primjenu, sterilne otopine za injekcijsku ili aerosolnu primjenu, u obliku trenutnog otpuštanja ili u obliku odgođenog otpuštanja.